Ally Bridge Group (NY) LLC In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Ally Bridge Group (NY) LLC reported 13 stock positions worth $63.0 million . Its top holding was Abivax SA-ADR (ABVX) at 15.0% of the portfolio, followed by Soleno Therapeutics (SLNO, 12.3% ) and Ataibeckley (11.1% ). Compared with Q3 2025, it opened 6 new positions, sold out of 11 and reduced 5. The biggest buy was a new position in Abivax SA-ADR (ABVX) and the biggest sale an exit from Madrigal Pharmaceuticals (MDGL).
Location NEW YORK, NY
CIK 0001822947
Portfolio Value $63.0M (Q4 2025) Holdings 13 stocks · $63.0M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q3 2025 ABVX Abivax SA-ADR 70,000 $9.4M New SLNO Soleno Therapeutics Inc. 168,029 $7.8M Reduce -44.5% ATAIBECKLEY INC 1,713,105 $7.0M Reduce -25.1% IVA Inventiva SA - ADR 1,500,000 $7.0M New NERV Minerva Neurosciences Inc. 1,655,500 $6.7M New PRAX Praxis Precision Medicines I 19,882 $5.9M New EWTX Edgewise Therapeutics Inc. 195,000 $4.8M New EPRX Eupraxia Pharmaceuticals Inc. 397,895 $3.0M Reduce -56.5% OVID Ovid Therapeutics Inc. 1,785,000 $2.9M New TSHA Taysha Gene Therapies Inc. 457,132 $2.5M Reduce -75.9% SLDB Solid Biosciences Inc. 413,625 $2.3M Reduce -24.7% WHWK Whitehawk Therapeutics Inc. 817,939 $2.0M No change PMN Promis Neurosciences Inc. 249,339 $1.7M No change
Options reported separately and not counted above: REPL calls ($11.7M), CMPS calls ($7.6M), EWTX puts ($6.2M), QURE calls ($4.8M), TSHA calls ($2.8M).
Portfolio Sells Q3 2025 → Q4 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2025 % Of Portfolio Change To Portfolio ▲ MDGL Madrigal Pharmaceuticals Inc. Sold out 0.00% −12.54 ASND Ascendis Pharma A/S Sold out 0.00% −8.50 LENZ Lenz Therapeutics Inc. Sold out 0.00% −6.84 AMLX Amylyx Pharmaceuticals Inc. Sold out 0.00% −4.98 CMPS Compass Pathways PLC Sold out 0.00% −4.92 SLNO Soleno Therapeutics Inc. Reduce -44.5% 12.35% −4.77 MNPR Monopar Therapeutics Inc. Sold out 0.00% −4.41 ARQT Arcutis Biotherapeutics Inc. Sold out 0.00% −3.68 MIND MEDICINE MINDMED INC Sold out 0.00% −3.57 TARS Tarsus Pharmaceuticals Inc. Sold out 0.00% −3.52 AVTX Avalo Therapeutics Inc. Sold out 0.00% −1.90 TECX Tectonic Therapeutic Inc. Sold out 0.00% −1.82 TSHA Taysha Gene Therapies Inc. Reduce -75.9% 3.99% −1.21 EPRX Eupraxia Pharmaceuticals Inc. Reduce -56.5% 4.77% +0.25 SLDB Solid Biosciences Inc. Reduce -24.7% 3.70% +0.87 ATAIBECKLEY INC Reduce -25.1% 11.12% +0.99
Portfolio Buys Q3 2025 → Q4 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2025 % Of Portfolio Change To Portfolio ▼ ABVX Abivax SA-ADR New 14.98% +14.98 IVA Inventiva SA - ADR New 11.07% +11.07 NERV Minerva Neurosciences Inc. New 10.56% +10.56 PRAX Praxis Precision Medicines I New 9.30% +9.30 EWTX Edgewise Therapeutics Inc. New 7.68% +7.68 OVID Ovid Therapeutics Inc. New 4.62% +4.62
Options Activity Q3 2025 → Q4 2025 Security Type Change vs Q3 2025 Underlying Shares Value ▼ SLNO Soleno Therapeutics Inc. call Sold out 250,000 $16.9Mbefore exit REPL Replimune Group Inc. call Reduce -66.7% 1,200,000 $11.7M CMPS Compass Pathways PLC call Reduce -4.0% 1,100,000 $7.6M EWTX Edgewise Therapeutics Inc. put New 250,000 $6.2M PRAX Praxis Precision Medicines I call Sold out 100,000 $5.3Mbefore exit QURE Uniqure NV call New 200,000 $4.8M TSHA Taysha Gene Therapies Inc. call New 500,000 $2.8M MLTX Moonlake Immunotherapeutics call Sold out 69,000 $495Kbefore exit ATYR Atyr Pharma Inc. call Sold out 600,000 $433Kbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 23 $77.6M NERV, PMN, TRAX, AXSM, ASMB Q1 2026 21 $100.7M PRAX, NERV, SLNO, OVID, CMPS Q4 2025 13 $63.0M ABVX, SLNO, ATAIBECKLEY INC, IVA, NERV Q3 2025 18 $119.4M SLNO, MDGL, ATAIBECKLEY INC, ASND, LENZ Q2 2025 24 $120.2M VRNA, SLNO, LENZ, MRUS, ULTRAGENYX PHARMACEUTICAL IN Q1 2025 28 $110.9M SWTX, VRNA, SLNO, AXSM, TARS Q4 2024 30 $116.6M ITCI, TARS, INSM, AXSM, XENE Q3 2024 29 $186.8M INSM, TARS, MRUS, CGON, BPMC Q2 2024 25 $167.9M SLNO, SRPT, GERN, MRUS, INSM Q1 2024 22 $179.9M BPMC, SLNO, CGON, XENE, VRNA